Overview

• Brainlab has indefinitely postponed its IPO while keeping open the possibility of a future listing.
• The company attributed its decision to current geopolitical uncertainties that it said have made market conditions unfavorable.
• Investors had oversubscribed the offer at the lower end of the €80–€100 price range for two million new shares and up to 3.2 million secondary shares.
• The postponement follows Autodoc’s delay and occurs in a German market where only Pfisterer and Innoscripta have completed small listings this year.
• Founded in 1989 with around 1,800 employees, Brainlab provides surgical planning software for brain and cancer procedures and planned to use IPO proceeds to expand into orthopaedics, cardiac and ENT markets.